SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Achilles Therapeutics plc ACHL NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • GB • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Achilles Therapeutics plc (ACHL) is a Biotechnology company in the Healthcare sector, currently trading at $1.48. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ACHL = $2 (+35.1% upside).

Net income is $70M (loss), growing at -32.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $5M against $142M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 8.57 (strong liquidity). Debt-to-assets is 2.9%. Total assets: $161M.

Analyst outlook: 2 / 5 analysts rate ACHL as buy (40%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).

$2.00

▲ 35.14% Upside

Average Price Target

The 12-month price target for Achilles Therapeutics plc is $2.00.

ACHL SharesGrow Score Overview

57/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 90/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 52/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ACHL

ACHL trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $2, implying +35.1% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

ACHL: +0%/yr revenue is, -32.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet ACHL: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 8.57 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

ACHL: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 5 analysts rate ACHL as buy (40%). Analyst consensus target is $2 (+35.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range0.63-1.51

Volume1.2M

Avg Volume (30D)1.28M

Market Cap$60.83M

Beta (1Y)1.25

Share Statistics

EPS (TTM)-1.74

Shares Outstanding$39.97M

IPO Date2021-03-31

Employees204

CEOIraj Ali

Financial Highlights & Ratios

Gross Profit$-4.73M

EBITDA$-70.44M

Net Income$-69.67M

Operating Income$-75.26M

Total Cash$131.54M

Total Debt$4.62M

Net Debt$-126.92M

Total Assets$161.46M

Price / Earnings (P/E)-0.9

Analyst Forecast

1Y Price Target$2.00

Target High$2.00

Target Low$2.00

Upside+35.1%

Rating ConsensusBuy

Analysts Covering5

Buy 40% Hold 20% Sell 40%

Price Target Summary

Company Info

CountryGB

ExchangeNASDAQ Global Select

CurrencyUSD

ISINUS00449L1026

Price Chart

ACHL

Achilles Therapeutics plc ↗ · NASDAQ Global Select

Healthcare • Biotechnology

0.63 52WK RANGE 1.51

People Also View

Nuvation Bio Inc.

CytomX Therapeutics, Inc.

Assembly Biosciences, Inc.

Spero Therapeutics, Inc.

Instil Bio, Inc.

Neoleukin Therapeutics, Inc.

Eli Lilly and Company

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message